<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The toxicity of high dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) in 23 leukemic children aged 1.5 years to 16 years 11 months was evaluated </plain></SENT>
<SENT sid="1" pm="."><plain>The group included 11 children with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), nine with <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ANLL), two with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in blastic crisis, and one with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Toxicity consisted of bone marrow suppression in <z:hpo ids='HP_0000001'>all</z:hpo> patients, with a mean nadir time of 11 days for platelets and granulocytes </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients experienced <z:hpo ids='HP_0002017'>nausea and vomiting</z:hpo>; 12 of 23 had drug induced <z:hpo ids='HP_0001945'>fever</z:hpo>; seven of 23 <z:hpo ids='HP_0000509'>conjunctivitis</z:hpo>; five of 23 mucositis; four of 23 <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, and one of 23 elevated transaminase with <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Adverse reactions were mild and reversible in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="5" pm="."><plain>No serious neurologic toxicity was seen </plain></SENT>
<SENT sid="6" pm="."><plain>The toxicity observed in four patients with prior cranial irradiation was not any different from nonirradiated patients </plain></SENT>
<SENT sid="7" pm="."><plain>The only life-threatening effect was <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, the consequences of which were generally well controlled with antibiotic therapy </plain></SENT>
<SENT sid="8" pm="."><plain>While this agent was effective in induction of remission in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients resistant to standard doses of Ara-C, it had no significant effect in a very small number of patients with relapsed ALL and <z:mp ids='MP_0005481'>CML</z:mp> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Side effects of high dose Ara-C though relatively substantial are manageable enough to warrant wider scale efficacy trials of this agent in childhood <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
</text></document>